EXTON, PA — August 14, 2025 — Leads & Copy — As gene therapies for transfusion-dependent β-thalassemia (TDT) roll out in the U.S., a debate is emerging within hematology: gene editing versus gene addition.
Recent physician survey data from Market DynamixTM: Transfusion-Dependent Thalassemia shows half of hematologists favor the CRISPR/Cas9-based therapy Casgevy, versus one-fifth for Zynteglo, a lentiviral vector-based therapy. Some express no strong preference, citing similar efficacy and safety profiles in trials.
Casgevy (exagamglogene autotemcel, Vertex/CRISPR Therapeutics) uses CRISPR/Cas9 gene editing to disable the BCL11A enhancer, reactivating fetal hemoglobin production. Zynteglo (betibeglogene autotemcel, bluebird bio) inserts a functional HBB (β-globin) gene into a patient’s hematopoietic stem cells, restoring normal hemoglobin production.
Physicians cite Casgevy’s novel CRISPR platform and accumulating real-world experience as compelling advantages. Others value Zynteglo’s longer track record and direct β-globin restoration.
Despite the promise of both therapies, physicians in suburban and rural areas report that demand exceeds capacity. High costs, lengthy insurance approvals, and constrained treatment slots can delay care.
TDT is a severe inherited blood disorder requiring lifelong transfusions. Gene therapy offers transfusion independence, but equitable access remains a challenge.
Spherix will continue to monitor the hemoglobinopathy market, including thalassemia, through annual Market DynamixTM and Patient Chart DynamixTM services.
Contact:
Sarah Hendry, Hematology Franchise Head
Sarah.hendry@spherixglobalinsights.com
4848794284
Source: Spherix Global Insights
